TJ Biopharma Announces Publication of Plonmarlimab Phase 2 Results in the Journal of Hematology & Oncology

TJ Biopharma reported Phase 2 results showing encouraging clinical responses and glucocorticoid-sparing potential in macrophage activation syndrome. The findings build on its work targeting GM-CSF in macrophage- and myeloid cell-driven inflammation; the provided article text contains no response rates, trial size, or other quantitative results.